<DOC>
	<DOCNO>NCT02537834</DOCNO>
	<brief_summary>An open-label , multicenter study evaluate 52-week long-term safety , tolerability efficacy Tofogliflozin GLP-1 analogue treatment type 2 diabetes mellitus .</brief_summary>
	<brief_title>Tofogliflozin GLP-1 Analogue Combination Trial</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>The subject age 20 75 year old type 2 diabetes mellitus ( T2DM ) The subject hemoglobin A1c ≧7.5 % ＜10.5 % The subject receive stable dose regimen GLP1 analogue 8 week Screening test The subject type 1 diabetes mellitus The subject Pregnancy lactation The subject Fasting Plasma Glucose ≧ 270 mg/dl The subject history metabolic acidosis , include diabetic ketoacidosis , within 1 year prior screen The subject myocardial infarction , stroke , heart failure require hospitalization drug alcohol abuse within previous 6 month The subject serum creatinine level great 2.0 mg/dL men 1.5 mg/dL woman The subject aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≧ 2.5 time upper limit reference range central laboratory test facility The subject receive treatment another investigational product nonapproved drug 3 month screen The subject history Tofogliflozin therapy The subject estimate glomerular filtration rate &lt; 30 mL/min/1.73 m^2 The subject frequently experience orthostatic hypotension The subject systolic blood pressure ≧ 180 mmHg diastolic blood pressure ≧ 100 mmHg The subject require change dose regiment follow drug within 4 week screening : Lipidlowering drug , Antihypertensive drug , Thyroid hormone drug , Uric acid lower drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>